Foradil - Novartis

• Validates DPI technology

• $10 million equity investment

• Manufacture finished product at Lyon facility

• Royalties & manufacturing revenues over 10%

• Foradil clinical trials  commenced Q3 1999

• Substantial royalties expected 2002 onwards

Previous slide

Next slide

Back to first slide

View graphic version